Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board of Directors of the at their ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.7 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Natural Biocon (India) Ltd, at its meeting held on May 29, 2025, approved the audited standalone financial results for Q4 and FY ended March 31, 2025, along with the profit & loss statement, balance sheet, and cash flow statement. Statutory auditor M/s Mayur Shah & Associates issued an unmodified (clean) opinion on the results. FY25 revenue declined sharply to Rs 834.81 lakhs from Rs 1,353.37 lakhs in FY24, a drop of about 38%. Net profit for FY25 fell to Rs 4.46 lakhs (vs Rs 15.27 lakhs in FY24), and Q4 FY25 swung to a loss of Rs 48.62 lakhs versus a profit of Rs 24.59 lakhs in Q3 FY25. The company raised Rs 1,945.35 lakhs through share issuance during the year, boosting total equity to Rs 3,187.03 lakhs, and made a fresh investment of Rs 2,112.37 lakhs in non-current financial assets. The company has zero financial indebtedness and reported positive operating cash flow of Rs 29.51 lakhs for FY25.
Sharp revenue contraction and a quarterly loss are negatives for shareholders, though the clean audit opinion, debt-free status, and fresh equity infusion provide some comfort. The weak earnings may pressure the stock in the short term.